Business Wire

Global Survey Shows Industrywide Priority to Modernize Clinical Trials for Faster Study Execution

6.10.2020 14:03:00 EEST | Business Wire | Press release

Share

Modernizing clinical trial operations is a top priority among life sciences companies according to the Veeva 2020 Unified Clinical Operations Survey Report, one of the largest-ever global surveys of clinical operations professionals. Findings from Veeva Systems (NYSE: VEEV) reveal an industrywide drive to streamline processes for increased efficiency, quality, and speed in trials.

The shift to modernize has been well underway in major clinical areas such as eTMF, for example, where the number of respondents using eTMF has quadrupled since 2014 (68% vs. 17% in 2014). COVID-19 is now accelerating sponsor and CRO adoption of advanced applications to seamlessly manage trials and improve study performance. This research shows a significant opportunity to bring together clinical landscapes for faster execution, especially important as sponsors and CROs need to keep existing trials running and accelerate new trial starts.

Almost all sponsors and CROs report a need to unify their clinical applications, and most respondents (83%) now have initiatives planned or underway. The top drivers include better visibility and oversight, reduced manual processes, and improved study quality, underscoring the industry's need to streamline end-to-end clinical processes and simplify information sharing for better trial performance.

Streamlining Collaboration and Information Exchange

Sponsors, CROs, and sites share a large amount of timely information that impacts trial outcomes. An over-reliance on manual methods, such as email and paper shipments, creates significant challenges with tracking and reporting, manual processes, and misfiled/missing documents.

All respondents report the need to simplify information exchange with study partners, signaling an urgency to find easier and more connected ways to collaborate. Reducing manual processes (75%), greater visibility and oversight (58%), and faster study execution (58%) are among the top drivers to improve information sharing during trials.

Advanced Clinical Applications Becoming the Norm

Many organizations have made progress in modernizing clinical processes and systems by adopting purpose-built applications. eClinical solutions such as EDC (91%), eTMF (78%), and CTMS (64%), are utilized by most sponsors and CROs, as function-specific technologies to support clinical trials become the industry standard.

Those using advanced clinical applications are reporting significant benefits. Sponsors and CROs using purpose-built CTMS applications see considerable improvements in compliance with standards, governance and oversight, and study performance metrics and reporting. CTMS applications are the most effective tool for managing end-to-end clinical trial processes compared with homegrown systems and manual spreadsheets.

Consistent with the industry's effort to streamline information sharing, more than one-third of respondents say faster collection of site essential documents and easier collaboration will improve study start-up. Manual processes like email and paper shipments to exchange trial documents with sites cause delays. Automating areas like contracts and budgets and site essential document collection are key to accelerating trials.

"Life sciences companies recognize the significant opportunity to improve how trials are run and are modernizing their clinical operations," said Jim Reilly, vice president, Vault R&D at Veeva Systems. "COVID-19 is accelerating the transition to more connected ways of working that will have a long-term positive impact on the efficiency and speed of drug development."

The Veeva 2020 Unified Clinical Operations Survey Report examines the life sciences industry's progress toward modernizing clinical operations by gathering the experiences and opinions of more than 500 clinical operations professionals from around the globe. The annual research details the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry's progress in its move to unify clinical trial systems and processes, and increase stakeholder engagement throughout study execution. The full report is available online at veeva.com/ClinicalSurvey.

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Research Highlights
Veeva 2020 Unified Clinical Operations Survey Report

The report examines the life sciences industry's progress toward modernizing clinical operations by gathering the experiences and opinions of more than 500 clinical operations professionals globally. The research details the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry's progress in its move to unify clinical trial systems and processes, and increase stakeholder engagement throughout study execution.

Modernizing Clinical Operations to Speed Study Execution

  • Most sponsors and CROs now utilize standalone, eClinical applications as they steadily adopt function-specific technologies to support clinical trials including, EDC (91%), eTMF (78%), and CTMS (64%).
  • Nearly all (98%) respondents say they have significant challenges with their clinical applications. The top three challenges – integrating multiple applications (70%), managing trial information across applications (57%), and reporting across multiple applications (56%) – are likely the result of system and process silos.
  • Most (98%) report the need to unify clinical applications, and 83% say their organizations now have initiatives planned or underway.
  • The need to unify clinical application landscapes is driven by better visibility and oversight (70%), reduced manual processes (69%), improved study quality (60%), faster study execution (56%), and improved collaboration (52%).

Improving the Flow of Information in Trials for Better Collaboration

  • All (100%) respondents say they need to improve information sharing between study partners to reduce manual processes (75%), improve visibility and oversight (58%), and speed trials (58%).
  • Email is the predominant way sponsors and CROs exchange information with sites (78%), followed by paper shipments (40%), and portals (38%).
  • Nearly all (99%) report significant challenges with the methods used to exchange information during clinical trials.
  • Managing information exchange via email and other traditional methods contribute to issues respondents have with tracking and reporting (67%), manual processes (64%), and misfiled/missing documents (53%).

Streamlining Study Start-up to Accelerate Cycle Times

  • All (100%) respondents say they need to improve study start-up processes.
  • More than one-third say faster collection of site essential documents (44%) and easier collaboration (42%) will improve study start-up, highlighting the importance of streamlined information sharing and collaboration to trial performance.
  • Majorities (81%) use spreadsheets to manage study start-up processes. Roughly half use eTMF (52%) and CTMS (50%) applications.

Digitizing Trial Processes for Higher Quality Results

  • The number of respondents using an eTMF application has quadrupled since 2014 (68% vs. 17% in 2014). The growth in eTMF adoption comes as organizations increasingly move away from general-purpose methods to manage TMF processes.
  • Sponsors and CROS using advanced CTMS applications to manage clinical studies report significant advantages over manual processes and other systems, including compliance with standards (58% versus 37%, respectively), governance and oversight (48% versus 38%, respectively), and study performance metrics and reporting (46% versus 32%, respectively).

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

a2z Radiology AI Receives EU MDR Certification for AI That Detects 182 Findings Across Head, Chest, Abdomen and Pelvis CT12.11.2026 10:00:00 EET | Press release

a2z Radiology AI Inc. today announced that a2z-Drafter has been certified under the EU Medical Device Regulation (MDR). The software supports triage, detection and report drafting on CT scans of the head, chest, abdomen and/or pelvis. “Radiology teams have had to piece together separate AI tools for each condition and body region,” said Samir Rajpurkar, co-founder and CEO of a2z Radiology AI. “a2z-Drafter is one product that works on head, chest and abdomen-pelvis CT scans and gives the radiologist a structured starting point for the report. This certification lets us bring that to radiology teams in the European Union.” a2z-Drafter detects 182 validated radiological findings on CT studies of the head, chest, abdomen and/or pelvis, with supplementary attributes for selected findings. The findings span acute conditions such as subarachnoid hemorrhage, midline shift, pneumothorax and bowel obstruction, findings that need prompt workup such as obstructing ureteral stones and aortic aneury

KiddeFenwal Secures A2P System Certification from Centre National de Prévention et de Protection in France12.11.2026 10:00:00 EET | Press release

KiddeFenwal, the global leader in fire protection and safety controls, has received an Assurance Prévention Protection (A2P) System Certification for its NATURA™ inert gas fire suppression system. The designation from France’s Centre National de Prévention et de Protection (CNPP), one of the most respected fire safety testing and certification organizations in Europe, illustrates how KiddeFenwal is expanding the reach of its industry-leading technologies throughout the world with the support of independent, third-party evaluators. “KiddeFenwal is grateful to CNPP for standing behind our proven NATURA™ system,” said Rekha Agrawal, CEO of KiddeFenwal. “The certification enables our systems to protect the facilities and institutions that matter most, such as data centers, battery energy storage systems and power generation applications. This will lead to stronger protections all throughout France.” Since its launch in 2019, KiddeFenwal’s NATURA™ has offered facilities an enhanced means of

Shahrukhz Residences by Danube: Exclusive Gauri Khan-Designed Penthouses Worth USD 5.35 Million Each Sell Out on Launch Day12.11.2026 09:30:00 EET | Press release

Danube Properties unveiled Shahrukhz Residences by Danube, its fully furnished waterfront development in Dubai Maritime City, at a grand launch event on November 11 at Coca-Cola Arena, Dubai, in presence of the Danube Group Founder and Chairman Rizwan Sajan, Shah Rukh Khan and Gauri Khan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111982153/en/ Shahrukhz Residences by Danube: Exclusive Gauri Khan-Designed Penthouses Worth USD 5.35 Million Each Sell Out on Launch Day (Photo: AETOSWire) Hosted by filmmaker Karan Johar, the event marked the second collaboration between Rizwan Sajan and SRK. A highlight of the evening was the announcement that all Gauri Khan-designed penthouses, each valued at USD 5.35 Million, had sold out on launch day. Expressing gratitude for the phenomenal response, Rizwan Sajan said, “Shahrukhz Residences is more than a development; it represents our ambition to create homes that bring together exce

Allianz Delivers Record Nine-month Result of 14.1 Billion Euros and Raises 2026 Outlook12.11.2026 08:06:00 EET | Press release

3Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111915059/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 44.4 billion euros, an internal growth of 3.0 percent1. Excellent contribution from Asset Management and good internal growth in Property-Casualty. Operating profit rises 6.2 percent to 4.7 billion euros, driven by an outstanding result from the Asset Management segment, attributable to higher business volume and margins, and a strong contribution from Life/Health. Shareholders’ core net income increases 1.2 percent to 2.9 billion euros. Adjusted for offsetting measures following the sale of the stake in our Indian JVs, underlying growth is 3 percent. 9M 2026 Total business volume at 143.0 billion euros, an internal growth of 3.8 percent 1 , driven by excellent growth in Asset Management and good internal growth in Property-Casualty. Operating profit rises 7.8 percent to 14.1 bil

LTM Brings AI-Powered Quantum Error Mitigation to IBM Quantum Functions Catalog12.11.2026 07:30:00 EET | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced that AI-QEM, its proprietary AI-powered Quantum Error Mitigation capability, is now available in the IBM Quantum Functions Catalog. With this milestone, LTM becomes the first Global Systems Integrator (GSI) worldwide to publish a function in the catalog. The IBM Quantum Functions Catalog is an ecosystem of partner-built quantum software services that simplify quantum workflows and enable researchers and enterprises to run quantum experiments more efficiently for algorithm development and application prototyping. AI-QEM is available as a circuit function, allowing users of eligible IBM Quantum access plans to apply LTM's error mitigation capability directly within their Qiskit workflows. Quantum computers are inherently susceptible to noise and errors that can impact computational outcomes. While conventional error mitigation techniques often require additional circuit executions, quantum processing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye